zacks.com / .zacks-com / Page 4

Medtronic eyes a $650 million acquisition of SPR, adding the FDA-cleared SPRINT PNS System to expand its chronic pain treatment offerings ahead of the fiscal 2027 closing.

Idaho Strategic's profitable gold business, rising earnings and lower valuation give it an edge over MP Materials in the rare-earth investment race.

AAP posts a surprise Q1 profit as comparable sales rise 3.5%, gross margin expands and Pro demand fuels the strongest comp growth in five years.

Keros faces a volatile setup after its Q1 miss, with a longer cash runway and leaner costs balanced against uncertain milestone-driven revenue.

Keros heads into 2026 with rinvatercept catalysts in DMD and ALS as investors watch phase II plans, orphan status and early clinical signals.

MMM faces ongoing Consumer segment softness as muted spending and weak housing weigh on demand, while cost controls and innovation aim to steady growth.

FLO beats fiscal first-quarter earnings and sales estimates as pricing gains and the Simple Mills acquisition lift revenues despite lower volumes.

CPAY shares jump 10.9% over the past month as Corporate Payments growth, acquisitions and cross-border activity boost momentum.

Market Awaits Revised Consumer Sentiment Numbers.

MGNI is gaining CTV share, expanding EBITDA margins and investing in AI - while The Trade Desk faces slower Q2 growth.